Boston Scientific Co. (NYSE:BSX) Shares Sold by International Assets Investment Management LLC

International Assets Investment Management LLC trimmed its holdings in Boston Scientific Co. (NYSE:BSX) by 95.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,078 shares of the medical equipment provider’s stock after selling 445,967 shares during the quarter. International Assets Investment Management LLC’s holdings in Boston Scientific were worth $1,972,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Private Advisor Group LLC increased its position in shares of Boston Scientific by 9.8% during the second quarter. Private Advisor Group LLC now owns 35,059 shares of the medical equipment provider’s stock worth $2,700,000 after purchasing an additional 3,143 shares in the last quarter. Savant Capital LLC grew its stake in Boston Scientific by 2.0% during the 2nd quarter. Savant Capital LLC now owns 14,174 shares of the medical equipment provider’s stock worth $1,092,000 after buying an additional 273 shares during the last quarter. First Foundation Advisors increased its position in Boston Scientific by 51.2% during the second quarter. First Foundation Advisors now owns 549 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 186 shares during the period. Prudential PLC lifted its stake in Boston Scientific by 6.8% in the second quarter. Prudential PLC now owns 34,685 shares of the medical equipment provider’s stock valued at $2,671,000 after buying an additional 2,209 shares during the last quarter. Finally, Wedbush Securities Inc. acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $251,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BTIG Research lifted their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a report on Monday, October 14th. Citigroup upped their target price on shares of Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Truist Financial increased their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Finally, Wells Fargo & Company increased their price objective on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.96.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,989 shares of company stock valued at $2,702,261. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $95.88 on Thursday. The firm has a market capitalization of $141.31 billion, a price-to-earnings ratio of 79.24, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The business’s 50 day simple moving average is $89.49 and its 200-day simple moving average is $83.59. Boston Scientific Co. has a 12 month low of $58.09 and a 12 month high of $97.13.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the previous year, the business earned $0.50 earnings per share. Boston Scientific’s quarterly revenue was up 19.3% compared to the same quarter last year. As a group, equities analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.